Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
bimekizumab - UCB4940
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Ankylosing Spondylitis | A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
AS0008 Completed |
NCT02963506 2016-001102-42 |
|
van der Heijde D., Arthritis Rheumatol 2019; 71(Suppl 10), abs 0937 | ||
| Ankylosing Spondylitis | A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis |
AS0009 Ongoing |
|||||
| Nonradiographic Axial Spondyloarthritis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis |
AS0010 Ongoing |
|
||||
| Ankylosing Spondylitis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
AS0011 Ongoing |
|||||
| Ankylosing Spondylitis | Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS) |
AS0013 Completed |
NCT03215277 | ||||
| Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (BE MOVING) |
AS0014 Ongoing |
|
||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
DV0002 Completed |
|
||||
| Psoriatic Arthritis | The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI). |
DV0004 Completed |
NCT04109976 | ||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
DV0006 Completed |
|
||||
| Hidradenitis Suppurativa | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. |
HS0001 Completed |
NCT03248531 |
|
Jemec G.B.E., Sayed C., Schmieder G., Weisman J., Rolleri R. et al. Experimental Dermatology 2020; 29(Suppl. 1):31–2 9th Conference of the European Hidradenitis Suppurativa Foundation (HS), February 5-7, 2020,; Athens, Greece |
||
| Hidradenitis Suppurativa |
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I) |
HS0003 Ongoing |
|||||
| Hidradenitis Suppurativa | A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II) |
HS0004 Ongoing |
|||||
| Psoriatic Arthritis | A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis |
PA0008 Completed |
NCT02969525 2016-001103-23 |
LINK |
Ritchlin C.T. et al. The Lancet 2020; 395(10222):427–40 |
||
| Psoriatic Arthritis | A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis |
PA0009 Completed |
Merola J., Behrens F., Kivitz A., Mease P., Mcinnes I. et al. Arthritis Rheumatol 2020; 72(S10):- 2020 Annual Meeting of the American College of Rheumatology (ACR) and 2020 Annual Meeting of the Association of Rheumatology Health Professionals (ARHP), November 05-09, 2020; ACR Convergence 2020 Virtual | ||||
Psoriatic Arthritis |
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0010 Ongoing |
|||||
| Psoriatic Arthritis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0011 Ongoing |
|||||
| Psoriatic Arthritis |
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0012 Ongoing |
|
||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0008 Completed |
NCT03412747 |
LINK |
|||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0009 Completed |
LINK |
Reich K. et al. Lancet 2021; 397(10273):487–98 | |||
| Chronic Plaque Psoriasis | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients with Chronic Plaque Psoriasis |
PS0010 Completed |
NCT02905006 |
LINK |
Papp K.A., et al. J Am Acad Dermatol 2018; 79(2):277–286 | ||
| Chronic Plaque Psoriasis | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis |
PS0011 Completed |
NCT03010527 |
Blauvelt, A. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), s. 1834 |
|||
| Chronic Plaque Psoriasis | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0013 Completed |
NCT03410992 |
LINK |
Gordon K.B., Foley P., Krueger J.G., Pinter A., Reich K. et al. Lancet 2021; 397(10273):475–86 | ||
Chronic Plaque Psoriasis |
A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0014 Ongoing |
|||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0015 Ongoing |
|||||
| Chronic Plaque Psoriasis | A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0016 Completed |
|||||
| Chronic Plaque Psoriasis | A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. |
PS0018 Completed |
|||||
| Rheumatoid arthritis | Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis |
RA0123 Completed |
NCT02430909 2014-003307-30 |
|
Glatt et al. Annals of the rheumatic diseases 2019 [ePub] | ||
| Ulcerative Colitis | A study to test the effectiveness of bimekizumab as a treatment for ulcerative colitis to look for unwanted side effects and to measure how the drug is distributed, modified and cleared from the body. |
UC0011 Terminated |
2016-000420-26 |
|